New results published in the prestigious New England Journal of Medicine show that later treatment is also efficacious in that it improves the patients' prospects of recovery.
Thrombolytic treatment with the clot-busting drug alteplase is the only available method of treating acute stroke caused by a blood clot in the brain. However, the treatment is only approved within three hours after onset of stroke, which means that relatively few patients manage to be in a position to receive treatment before this time threshold has been crossed.
Scientists at the Swedish medical university Karolinska Institutet and the international network SITS (Safe Implementation of Treatments in Stroke) recently presented novel findings that may question present recommendations. The study, which was published in the Lancet on 15 September, demonstrated that thrombolysis administered within three to four and a half hours after a stroke was just as safe as that given within the three-hour time window.
These results are now corroborated by a study published in the top-ranking journal New England Journal of Medicine and co-authored by scientists from Karolinska Institutet. The study in question was a randomised comparative analysis of thrombolysis administered in the 3 to 4.5-hour interval and a placebo control, and shows that thrombolysis is more effective than control treatment and that many patients had recovered after three months.
"Both studies support the idea that the time window for thrombolysis should be extended, and this from the perspective of both safety and efficacy," says Professor Nils Wahlgren, who co-led both studies.
In this present study, 52.4 per cent of the patients who received thrombolysis recovered within three months, compared to 45.2 per cent of the placebo group - a statistically significant difference. A total of 418 patients received thrombolysis and 403 a placebo. The proportion of symptomatic haemorrhages was higher in the experimental group than in the control group, but no higher than in the currently approved 0 to 3-hour interval.
The results of the two studies are to be discussed at Karolinska Stroke Update, an international expert conference to be held from 16 to 18 November in Stockholm, at which a decision is due to be taken on whether the European guidelines should be changed.
Publication: 'Alteplase Compared with Placebo within 3 to 4.5 Hours for Acute Ischemic Stroke' Werner Hacke, Markku Kaste, Erich Bluhmki, Miroslav Brozman, Antoni Dávalos, Donata Guidetti, Vincent Larrue, Kennedy R Lees, Zakaria Medeghri, Thomas Machnig, Dietmar Schneider, Rüdiger von Kummer, Nils Wahlgren, and Danilo Toni, for the European Cooperative Acute Stroke Study (ECASS) investigators, New England Journal of Medicine, 25 September 2008
Earlier publication: 'Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke: an observational study', Nils Wahlgren, Niaz Ahmed, Antoni Dávalos, Werner Hacke, Mónica Millán, Keith Muir, Risto O Roine, Danilo Toni, Kennedy R Lees, for the SITS investigators, Lancet 16 September 2006
For further information, please contact:Professor Nils Wahlgren
Katarina Sternudd | idw
Biofilm discovery suggests new way to prevent dangerous infections
23.05.2017 | University of Texas at Austin
Another reason to exercise: Burning bone fat -- a key to better bone health
19.05.2017 | University of North Carolina Health Care
Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.
Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....
Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.
The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....
An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.
We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...
Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.
Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...
An Australian-Chinese research team has created the world's thinnest hologram, paving the way towards the integration of 3D holography into everyday...
24.05.2017 | Event News
23.05.2017 | Event News
22.05.2017 | Event News
26.05.2017 | Life Sciences
26.05.2017 | Life Sciences
26.05.2017 | Physics and Astronomy